Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Imaging in Central Nervous System Drug Discovery
Roger N. Gunn, Eugenii A. Rabiner
Seminars in Nuclear Medicine (2016) Vol. 47, Iss. 1, pp. 89-98
Closed Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels
M. Madsen, Patrick M. Fisher, Daniel Burmester, et al.
Neuropsychopharmacology (2019) Vol. 44, Iss. 7, pp. 1328-1334
Open Access | Times Cited: 378
2-Arachidonoylglycerol Modulation of Anxiety and Stress Adaptation: From Grass Roots to Novel Therapeutics
Gaurav Bedse, Mathew N. Hill, Sachin Patel
Biological Psychiatry (2020) Vol. 88, Iss. 7, pp. 520-530
Open Access | Times Cited: 54
The Future of (Radio)‐Labeled Compounds in Research and Development within the Life Science Industry
Volker Derdau, Charles S. Elmore, Thomas Härtung, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 52
Open Access | Times Cited: 16
Neuroimaging in psychedelic drug development: past, present, and future
Matthew B. Wall, Rebecca Harding, Rayyan Zafar, et al.
Molecular Psychiatry (2023) Vol. 28, Iss. 9, pp. 3573-3580
Open Access | Times Cited: 16
The role of fMRI in drug development
Owen Carmichael, Adam J. Schwarz, Christopher H. Chatham, et al.
Drug Discovery Today (2017) Vol. 23, Iss. 2, pp. 333-348
Open Access | Times Cited: 60
Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study
Ryan T. Terry-Lorenzo, Daniel Albrecht, Sabrinia Crouch, et al.
Neuropsychopharmacology (2025)
Closed Access
Solid-phase supported direct 18F-radiofluorination of peptides
Eduardo Fernandes, Line Bruhn Schneider Knudsen, Andreas Kjær, et al.
Bioorganic & Medicinal Chemistry Letters (2025), pp. 130118-130118
Open Access
Ketanserin exhibits dose- and concentration-proportional serotonin 2A receptor occupancy in healthy individuals: Relevance for psychedelic research
Friederike Holze, M. Madsen, Claus Svarer, et al.
European Neuropsychopharmacology (2024) Vol. 88, pp. 43-48
Closed Access | Times Cited: 4
In vivo imaging biomarkers of neuroinflammation in the development and assessment of stroke therapies - towards clinical translation
Bastian Zinnhardt, Maximilian Wiesmann, Lisa Honold, et al.
Theranostics (2018) Vol. 8, Iss. 10, pp. 2603-2620
Open Access | Times Cited: 35
Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017)
Dorota Łażewska, Katarzyna Kieć‐Kononowicz
Expert Opinion on Therapeutic Patents (2018) Vol. 28, Iss. 3, pp. 175-196
Closed Access | Times Cited: 29
News and views on in-vivo imaging of neurotransmission using PET and MRI
Christin Y. Sander, Swen Hesse
The Quarterly Journal of Nuclear Medicine and Molecular Imaging (2017) Vol. 61, Iss. 4
Open Access | Times Cited: 28
Clinical Applications of Small-molecule PET Radiotracers: Current Progress and Future Outlook
Amy L. Va̅vere, Peter J. H. Scott
Seminars in Nuclear Medicine (2017) Vol. 47, Iss. 5, pp. 429-453
Closed Access | Times Cited: 27
PET as a Translational Tool in Drug Development for Neuroscience Compounds
Andrea Varrone, Christoffer Bundgaard, Benny Bang‐Andersen
Clinical Pharmacology & Therapeutics (2022) Vol. 111, Iss. 4, pp. 774-785
Open Access | Times Cited: 13
Positron Emission Tomography of Neuroimmune Responses in Humans: Insights and Intricacies
Nakul Ravi Raval, Reagan R. Wetherill, Corinde E. Wiers, et al.
Seminars in Nuclear Medicine (2022) Vol. 53, Iss. 2, pp. 213-229
Open Access | Times Cited: 12
Less Exploited GPCRs in Precision Medicine: Targets for Molecular Imaging and Theranostics
João Franco Machado, Rúben D. M. Silva, Rita Melo, et al.
Molecules (2018) Vol. 24, Iss. 1, pp. 49-49
Open Access | Times Cited: 16
Mode of Action of Shan‐Zhu‐Yu (Cornus officinalis Sieb. et Zucc.) in the Treatment of Depression Based on Network Pharmacology
Ping Liu, Ping Yang, Lan Zhang
Evidence-based Complementary and Alternative Medicine (2020) Vol. 2020, Iss. 1
Open Access | Times Cited: 15
Contribution of Intravital Neuroimaging to Study Animal Models of Multiple Sclerosis
Emeline Buttigieg, Anja Scheller, Bilal El Waly, et al.
Neurotherapeutics (2023) Vol. 20, Iss. 1, pp. 22-38
Open Access | Times Cited: 5
Likelihood estimation of drug occupancy for brain PET studies
Martin Schain, Francesca Zanderigo, R. Todd Ogden
NeuroImage (2018) Vol. 178, pp. 255-265
Closed Access | Times Cited: 13
Synthesis and preclinical evaluation of [11C]MTP38 as a novel PET ligand for phosphodiesterase 7 in the brain
Naoyuki Obokata, Chie Seki, Takeshi Hirata, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2021) Vol. 48, Iss. 10, pp. 3101-3112
Open Access | Times Cited: 11
Has molecular imaging delivered to drug development?
Philip S. Murphy, Neel Patel, Timothy J. McCarthy
Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences (2017) Vol. 375, Iss. 2107, pp. 20170112-20170112
Open Access | Times Cited: 6
Lessons learned from using fMRI in the early clinical development of a mu-opioid receptor antagonist for disorders of compulsive consumption
Pradeep J. Nathan, Geor Bakker
Psychopharmacology (2020) Vol. 238, Iss. 5, pp. 1255-1263
Closed Access | Times Cited: 6
Kinetic models for estimating occupancy from single-scan PET displacement studies
Gjertrud Louise Laurell, Pontus Plavén‐Sigray, Annette Johansen, et al.
Journal of Cerebral Blood Flow & Metabolism (2023) Vol. 43, Iss. 9, pp. 1544-1556
Closed Access | Times Cited: 2
Designing drug occupancy studies with PET neuroimaging: Sample size, occupancy ranges and analytical methods
Gjertrud Louise Laurell, Pontus Plavén‐Sigray, Claus Svarer, et al.
NeuroImage (2022) Vol. 263, pp. 119620-119620
Open Access | Times Cited: 4
Regulatory considerations for the use of biomarkers and personalized medicine in CNS drug development
Chukwuebuka Emmanuel Umeyor, Abhit Nayak, Emmanuel Uronnachi, et al.
Elsevier eBooks (2024), pp. 441-474
Closed Access
Synthesis and preclinical evaluation of [11C]MTP38 as a novel PET ligand for phosphodiesterase 7 in the brain
Naoyuki Obokata, Chie Seki, Takeshi Hirata, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top